Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists

Orly Vardeny, Muthiah Vaduganathan

Research output: Contribution to journalReview articlepeer-review

44 Scopus citations


The sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of glucose-lowering therapies that have been shown to reduce risks of heart failure (HF) events in patients with type 2 diabetes mellitus (T2DM) at high-risk for or with cardiovascular disease. The United States Food and Drug Administration has expanded the regulatory label for empagliflozin and canagliflozin for use to lower cardiovascular risk in patients with T2DM and cardiovascular disease. SGLT2 inhibitors are being actively studied in the treatment of patients with HF, including in those without diabetes mellitus. Despite the accumulating data supporting this class of therapies in HF prevention, cardiologists infrequently prescribe SGLT2 inhibitors, potentially due to lack of familiarity with their use. We provide an up-to-date practical guide highlighting important elements for treatment initiation, dosing, anticipated adverse effects, and barriers to uptake.

Original languageEnglish (US)
Pages (from-to)169-172
Number of pages4
JournalJACC: Heart Failure
Issue number2
StatePublished - Feb 2019

Bibliographical note

Publisher Copyright:
© 2019 American College of Cardiology Foundation


  • comorbidities
  • diabetes mellitus
  • heart failure
  • prevention


Dive into the research topics of 'Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists'. Together they form a unique fingerprint.

Cite this